このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

ステロイドに失敗した原発性免疫性血小板減少症患者におけるエルトロンボパグに加えて、イアルマブ対プラセボの有効性と安全性の研究 (VAYHIT2)

2026年11月5日 更新者:Novartis Pharmaceuticals

一次ステロイド治療(VAYHIT2)後に反応が不十分または再発した原発性免疫性血小板減少症(ITP)患者を対象に、エルトロンボパグに加えてIanalumab(VAY736)とプラセボを比較した第3相ランダム化二重盲検試験

The purpose of this study is to evaluate the effect of two different doses of ianalumab added to eltrombopag to prolong Time to Treatment Failure (TTF) in adults with primary ITP who failed previous first-line treatment with steroids.

調査の概要

詳細な説明

This is a multicenter, randomized, double-blinded phase 3 study to assess efficacy and safety of two different doses of ianalumab versus placebo in addition to eltrombopag in adults with primary ITP (platelet count <30 G/L) who failed previous first-line treatment with corticosteroids.

After completion of the screening period, the participants will enter the randomized treatment period (ianalumab/placebo with eltrombopag) followed by the eltrombopag tapering period. Afterwards, all participants will enter the follow-up period to be monitored for efficacy and safety or safety only depending on how the participants responded to the study treatment.

研究の種類

介入

入学 (実際)

152

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Arizona
      • Yuma、Arizona、アメリカ、85364
        • Yuma Regional Medical Center
    • Colorado
      • Aurora、Colorado、アメリカ、80045
        • University of Colorado Anschutz
    • Illinois
      • Evanston、Illinois、アメリカ、60201
        • Endeavor Health
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02215
        • Boston Medical Center
      • Worcester、Massachusetts、アメリカ、01665
        • UMASS Memorial Medical Center
    • Michigan
      • Farmington Hills、Michigan、アメリカ、48334
        • Michigan Center of Medical Research
    • Montana
      • Billings、Montana、アメリカ、59102
        • St Vincent Frontier Cancer Center
    • New York
      • Nyack、New York、アメリカ、10960
        • Hematology Oncology Association of Rockland
      • The Bronx、New York、アメリカ、10461
        • Montefiore Medical Center
      • CABA、アルゼンチン、C1181ACH
        • Novartis Investigative Site
      • London、イギリス、W12 0HS
        • Novartis Investigative Site
      • London、イギリス、E1 1BB
        • Novartis Investigative Site
      • Oxford、イギリス、OX3 7LE
        • Novartis Investigative Site
    • BO
      • Bologna、BO、イタリア、40138
        • Novartis Investigative Site
    • RM
      • Roma、RM、イタリア、00168
        • Novartis Investigative Site
      • Roma、RM、イタリア、00133
        • Novartis Investigative Site
    • TS
      • Trieste、TS、イタリア、34129
        • Novartis Investigative Site
    • Uttarakhand
      • Rishikesh、Uttarakhand、インド、249203
        • Novartis Investigative Site
    • West Bengal
      • Kolkata、West Bengal、インド、700014
        • Novartis Investigative Site
      • Utrecht、オランダ、3584 CX
        • Novartis Investigative Site
    • South Holland
      • Leiden、South Holland、オランダ、2333 ZA
        • Novartis Investigative Site
      • Vienna、オーストリア、1090
        • Novartis Investigative Site
      • Singapore、シンガポール、119074
        • Novartis Investigative Site
      • Singapore、シンガポール、169608
        • Novartis Investigative Site
      • Salamanca、スペイン、37007
        • Novartis Investigative Site
    • A Coruna
      • Santiago Compostela、A Coruna、スペイン、15706
        • Novartis Investigative Site
      • Bangkok、タイ、10700
        • Novartis Investigative Site
      • Chiang Mai、タイ、50200
        • Novartis Investigative Site
      • Brno、チェコ、625 00
        • Novartis Investigative Site
      • Prague、チェコ、128 08
        • Novartis Investigative Site
      • Prague、チェコ、100 34
        • Novartis Investigative Site
      • Izmir、トルコ(Türkiye)、35100
        • Novartis Investigative Site
    • Atakum
      • Samsun、Atakum、トルコ(Türkiye)、55200
        • Novartis Investigative Site
    • Bilkent Cankaya
      • Ankara、Bilkent Cankaya、トルコ(Türkiye)、06800
        • Novartis Investigative Site
    • Efeler
      • Aydin、Efeler、トルコ(Türkiye)、09100
        • Novartis Investigative Site
    • Fatih
      • Istanbul、Fatih、トルコ(Türkiye)、34098
        • Novartis Investigative Site
      • Dresden、ドイツ、01307
        • Novartis Investigative Site
    • North Rhine-Westphalia
      • Cologne、North Rhine-Westphalia、ドイツ、50937
        • Novartis Investigative Site
    • Saxony
      • Dresden、Saxony、ドイツ、01307
        • Novartis Investigative Site
    • Thuringia
      • Jena、Thuringia、ドイツ、07740
        • Novartis Investigative Site
      • Budapest、ハンガリー、1083
        • Novartis Investigative Site
    • Hajdu Bihar Megye
      • Debrecen、Hajdu Bihar Megye、ハンガリー、4032
        • Novartis Investigative Site
      • Makati City、フィリピン、1229
        • Novartis Investigative Site
      • Quezon、フィリピン、1102
        • Novartis Investigative Site
      • Blois、フランス、41000
        • Novartis Investigative Site
      • Le Mans、フランス、72000
        • Novartis Investigative Site
    • Namur
      • Yvoir、Namur、ベルギー、5530
        • Novartis Investigative Site
    • West Vlaanderen
      • Roeselare、West Vlaanderen、ベルギー、8800
        • Novartis Investigative Site
      • George Town、マレーシア、10050
        • Novartis Investigative Site
      • Johor Bahru、マレーシア、80100
        • Novartis Investigative Site
      • Kuala Selangor、マレーシア、68000
        • Novartis Investigative Site
    • Pulau Pinang
      • George Town、Pulau Pinang、マレーシア、10450
        • Novartis Investigative Site
    • Sabah
      • Kota Kinabalu、Sabah、マレーシア、88586
        • Novartis Investigative Site
    • Selangor
      • Subang Jaya、Selangor、マレーシア、47500
        • Novartis Investigative Site
    • Coahuila
      • Saltillo、Coahuila、メキシコ、25230
        • Novartis Investigative Site
    • Michoacán
      • Morelia、Michoacán、メキシコ、58260
        • Novartis Investigative Site
    • Nuevo León
      • Monterrey、Nuevo León、メキシコ、64460
        • Novartis Investigative Site
      • Timișoara、ルーマニア、300079
        • Novartis Investigative Site
    • Dolj
      • Craiova、Dolj、ルーマニア、200136
        • Novartis Investigative Site
      • Beijing、中国、100730
        • Novartis Investigative Site
      • Jinan、中国、250012
        • Novartis Investigative Site
      • Tianjin、中国、300020
        • Novartis Investigative Site
    • Guangdong
      • Guangzhou、Guangdong、中国、510515
        • Novartis Investigative Site
    • Hubei
      • Wuhan、Hubei、中国、430022
        • Novartis Investigative Site
    • Shandong
      • Binzhou、Shandong、中国、256603
        • Novartis Investigative Site
    • Zhejiang
      • Hangzhou、Zhejiang、中国、310003
        • Novartis Investigative Site
      • Taoyuan、台湾、33305
        • Novartis Investigative Site
      • Kumamoto、日本、8600008
        • Novartis Investigative Site
    • Aichi-ken
      • Nagoya、Aichi-ken、日本、4538511
        • Novartis Investigative Site
    • Osaka
      • Osaka、Osaka、日本、5400006
        • Novartis Investigative Site
      • Suita、Osaka、日本、5650871
        • Novartis Investigative Site
    • Yamanashi
      • Kofu、Yamanashi、日本、4008506
        • Novartis Investigative Site
      • Jeollanam、韓国、519763
        • Novartis Investigative Site
      • Seoul、韓国、06591
        • Novartis Investigative Site

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~100年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Key Inclusion criteria

  1. Male or female patients aged 18 years and older on the day of signing the informed consent.
  2. A signed informed consent must be obtained prior to participation in the study.
  3. A diagnosis of primary ITP, with insufficient response to, or relapse after a first-line corticosteroid therapy ± IVIG.
  4. Patient with platelet count <30G/L (whom eltrombopag is clinically indicated as per physician's discretion) and with no contraindication to receive eltrombopag

Key Exclusion criteria

  1. ITP patients who received second-line ITP treatments (other than steroid therapy± IVIG) including splenectomy. However, patients exposed to thrombopoietin receptor agonists (TPO-RAs) for a limited time (max one week) before screening are eligible.
  2. Patients with key lab abnormalities and patients with Evans syndrome or any other cytopenia, (patients with low grade anemia related to bleeding or iron deficiency are eligible).
  3. Patients with history of clinically significant hematological disorders, or with marked altered hematologic parameters
  4. Patients with current or history of life-threatening bleeding
  5. Patient that are Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Hepatitis B surface Antigen (HBsAg)/ Hepatitis B core antibody (HBcAb)-positive. HBcAb-positive patients can be enrolled if HBsAg negative, HBV DNA negative, no pre-existing liver fibrosis is present and antiviral prophylaxis is given
  6. Patients with known active or uncontrolled infection requiring systemic treatment during screening period
  7. Patients with hepatic impairment
  8. Patients with concurrent coagulation disorders and/or receiving antiplatelet or anticoagulant medication with an exemption of low dose of acetylsalicylic acid (≤150 mg daily)
  9. Nursing (breast feeding) or pregnant women

Other protocol-defined inclusion/exclusion criteria may apply.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:Treatment arm 1 - Lower dose

Participants will receive eltrombopag and ianalumab lower dose

Concentrate for solution for infusion for intravenous use

他の名前:
  • VAY736

Film-coated tablet for oral use

他の名前:
  • ETB115
実験的:Treatment arm 2 - Higher dose

Participants will receive eltrombopag and ianalumab higher dose

Concentrate for solution for infusion for intravenous use

他の名前:
  • VAY736

Film-coated tablet for oral use

他の名前:
  • ETB115
プラセボコンパレーター:Treatment arm 3 - Placebo

Participants will receive eltrombopag and placebo

Film-coated tablet for oral use

他の名前:
  • ETB115

Concentrate for solution for infusion for intravenous use.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Time from randomization until treatment failure
時間枠:Randomization to until end of study (up to 39 months after randomization of last participant)

Time from randomization until treatment failure is defined as the time from randomization date until the first of the following events indicative of treatment failure:

  • platelet count below 30 G/L
  • start of a new ITP treatment
  • need for a rescue treatment
  • ineligibility to taper or inability to discontinue eltrombopag
  • death
Randomization to until end of study (up to 39 months after randomization of last participant)

二次結果の測定

結果測定
メジャーの説明
時間枠
Stable response at 6 months (Key Secondary Endpoint)
時間枠:At 6 months

Percentage of participants with at least 3 platelet count collected at month 6 (between study days 121 and 183 and at least 75% of platelet counts qualified as a response).

At 6 months
Complete Response rate at each timepoint
時間枠:Randomization to until end of study (up to 39 months after randomization of last participant)

Percentage of participants with any platelet count of at least 100 G/L in the absence of rescue treatment or new ITP treatment

Randomization to until end of study (up to 39 months after randomization of last participant)
Response rate at each timepoint
時間枠:Randomization to until end of study (up to 39 months after randomization of last participant)

Percentage of participants with any platelet count of at least 50 G/L in the absence of rescue treatment or new ITP treatment

Randomization to until end of study (up to 39 months after randomization of last participant)
Best response rate across all timepoints
時間枠:Randomization to until end of study (up to 39 months after randomization of last participant)

Percentage of participants with a best response rate of either response or complete response

Randomization to until end of study (up to 39 months after randomization of last participant)
Time to first response/time to first complete response
時間枠:Time from randomization up to the longest observed treatment period duration

Time from randomization to date of first response and time from randomization to date of first complete response

Time from randomization up to the longest observed treatment period duration
Duration of response
時間枠:Randomization to until end of study (up to 39 months after randomization of last participant)

Time from achievement of response to treatment failure.

Randomization to until end of study (up to 39 months after randomization of last participant)
Stable response at 1 year
時間枠:At 1 year

Percentage of participants with at least 2 platelet count collected at year 1 (between study days 296 and 379 and at least 66% of platelet counts qualified as a response).

At 1 year
Duration of complete response
時間枠:Randomization to end of study (up to 39 months after randomization of last participant)

Time from achievement of complete response to loss of complete response stable response at 1 year period

Randomization to end of study (up to 39 months after randomization of last participant)
Rate of participants who successfully taper and discontinue eltrombopag in each treatment arm
時間枠:up to week 24

Probability to be treatment failure-free (as defined for the primary efficacy endpoint)

up to week 24
Percentage of participants with bleeding events according to World Health Organization (WHO)
時間枠:Randomization to until end of study (up to 39 months after randomization of last participant)

Percentage of participants reporting bleeding events according to WHO bleeding scale

Randomization to until end of study (up to 39 months after randomization of last participant)
Number of participants receiving rescue treatment
時間枠:Randomization to until end of study (up to 39 months after randomization of last participant)

Number of participants who are in need of rescue treatment in each treatment arm

Randomization to until end of study (up to 39 months after randomization of last participant)
Percentage of participants receiving rescue treatment
時間枠:Randomization to until end of study (up to 39 months after randomization of last participant)

Percentage of participants who are in need of rescue treatment

Randomization to until end of study (up to 39 months after randomization of last participant)
Change from baseline in the frequency of CD19+ B-cell counts
時間枠:Randomization to until end of study (up to 39 months after randomization of last participant)

Post-baseline frequency of CD19+ B-cell counts (percentage within CD45) compared to baseline

Randomization to until end of study (up to 39 months after randomization of last participant)
Change from baseline in the absolute number of CD19+ B-cell counts
時間枠:Randomization to until end of study (up to 39 months after randomization of last participant)

Post-baseline absolute number of CD19+ B-cell counts compared to baseline

Randomization to until end of study (up to 39 months after randomization of last participant)
Change from baseline on T-score of the PROMIS SF v1.0 Fatigue 13a
時間枠:From screening (baseline) until end of study (up 39 months after randomization of last participant)

The Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v1.0 Fatigue 13a includes 13 items that assess fatigue in adults.

From screening (baseline) until end of study (up 39 months after randomization of last participant)
Change from baseline in ITP PAQ domain scores of symptoms, fatigue, bother (uncomfortable), activity
時間枠:From screening (baseline) until end of study (up 39 months after randomization of last participant)

The ITP-PAQ is a 44 item scale for measuring HRQoL in adults with ITP across ten scales: Symptoms, Bother-Physical Health, Fatigue/Sleep, Activity, Fear, Psychological Health, Work, Social Activity, Women´s Reproductive Health, overall QoL. Each item is rated on a Likert type scale. Each scale is scored from 0 to 100. Higher scores represent better HRQoL.

From screening (baseline) until end of study (up 39 months after randomization of last participant)
Time to first occurence of B-cell recovery defined as ≥80% of baseline ≥50 cells/µL
時間枠:Randomization to until end of study (up to 39 months after randomization of last participant)

Time to B-cell recovery defined as ≥80% of baseline or ≥50 cells/µL

Randomization to until end of study (up to 39 months after randomization of last participant)
Change from baseline in immunoglobulins
時間枠:Randomization to until end of study (up to 39 months after randomization of last participant)

Change from baseline in immunoglobulin levels

Randomization to until end of study (up to 39 months after randomization of last participant)
PK parameters: AUClast
時間枠:After first dose (pre-dose, EOI, 168, 336 and 504 hours post dose) and after last dose (pre-dose, EOI, 336, 672, 2016, 3360 hours post dose)

AUClast: Area under the curve from time zero to the last measurable concentration sampling time (tlast)

After first dose (pre-dose, EOI, 168, 336 and 504 hours post dose) and after last dose (pre-dose, EOI, 336, 672, 2016, 3360 hours post dose)
PK parameters: AUCtau
時間枠:After first dose (pre-dose, EOI, 168, 336 and 504 hours post dose) and after last dose (pre-dose, EOI, 336, 672, 2016, 3360 hours post dose)

AUCtau: Area under the curve calculated to the end of a dosing interval (tau)

After first dose (pre-dose, EOI, 168, 336 and 504 hours post dose) and after last dose (pre-dose, EOI, 336, 672, 2016, 3360 hours post dose)
PK parameters: Cmax
時間枠:After first dose (pre-dose, EOI, 168, 336 and 504 hours post dose) and after last dose (pre-dose, EOI, 336, 672, 2016, 3360 hours post dose)

Maximum (peak) observed plasma, blood, serum or other body fluid drug concentration

After first dose (pre-dose, EOI, 168, 336 and 504 hours post dose) and after last dose (pre-dose, EOI, 336, 672, 2016, 3360 hours post dose)
PK parameters: Tmax
時間枠:After first dose (pre-dose, EOI, 168, 336 and 504 hours post dose) and after last dose (pre-dose, EOI, 336, 672, 2016, 3360 hours post dose)

Time to reach maximum (peak) observed plasma, blood, serum or other body fluid drug concentration

After first dose (pre-dose, EOI, 168, 336 and 504 hours post dose) and after last dose (pre-dose, EOI, 336, 672, 2016, 3360 hours post dose)
PK parameters: Accumulation ratio Racc
時間枠:After last dose (pre-dose, EOI, 336, 672, 2016, 3360 hours post dose)

Accumulation ratio calculated using AUC values obtained after the last and first dose

After last dose (pre-dose, EOI, 336, 672, 2016, 3360 hours post dose)
Incidence of anti-ianalumab antibodies in serum (ADA assay) over time
時間枠:up to week 33

Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants assessing the immunogenicity of ianalumab

up to week 33
Titer of anti-ianalumab antibodies in serum (ADA assay) over time
時間枠:up to week 33

Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants assessing the immunogenicity of ianalumab

up to week 33

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Novartis Pharmaceuticals、Novartis Pharmaceuticals

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年2月2日

一次修了 (実際)

2025年6月19日

研究の完了 (推定)

2028年4月8日

試験登録日

最初に提出

2022年11月23日

QC基準を満たした最初の提出物

2022年12月14日

最初の投稿 (実際)

2022年12月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月9日

QC基準を満たした最後の更新が送信されました

2026年11月5日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する